ASH Annual Meeting & Exposition: Leukemia | Conference

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML
January 21, 2021

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML
January 14, 2021

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients
January 06, 2021

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.